Results 141 to 150 of about 152,178 (350)

Acute Effect on QT Dispersion and Cardiac Function of Trastuzumab [PDF]

, 2014
Özgür Tanrıverdi
openalex   +1 more source

Data from Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer

, 2023
Michihiro Ishida, Shunsuke Kagawa, Kyoko Shimoyama, Kiyoto Takehara, Kazuhiro Noma, Shunsuke Tanabe, Yasuhiro Shirakawa, Hiroshi Tazawa, Hisataka Kobayashi, Toshiyoshi Fujiwara   +9 more
openalex   +1 more source

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Journal of Clinical Oncology, 2018
Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous ...
A. Fader, D. Roque, E. Siegel, N. Buza, P. Hui, O. Abdelghany, S. Chambers, A. Secord, L. Havrilesky, D. O’Malley, F. Backes, N. Nevadunsky, B. Edraki, D. Pikaart, W. Lowery, K. ElSahwi, P. Celano, S. Bellone, M. Azodi, B. Litkouhi, E. Ratner, D. Silasi, P. Schwartz, A. Santin   +23 more
semanticscholar   +1 more source

Mass spectrometry‐based mitochondrial proteomics for cancer biomarker discovery

VIEW, EarlyView.
Figure.1 Schematic diagram of MS‐based mitochondrial proteomics for cancer biomarker discovery. The workflow highlights the integration of advanced technological platforms in mitochondrial proteomics and their application in cancer biomarker discovery.
Zheng Cao, ZiKun Song, Weijie Zhou, Xiaohui Liu, Yanling Liu, Peng R. Chen, Kun Qian   +6 more
wiley   +1 more source

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

Breast Cancer Research, 2019
Background Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology.
Sònia Palomeras, Ángel Diaz-Lagares, Gemma Viñas, Fernando Setien, Humberto J. Ferreira, Glòria Oliveras, Ana B. Crujeiras, Alejandro Hernández, David H. Lum, Alana L. Welm, Manel Esteller, Teresa Puig   +11 more
doaj   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer. [PDF]

Cancer Innov
Potential biomarkers for the development of targeted radionuclide therapy that can be employed in the treatment of breast cancer have been summarised in the review. They include receptor markers of ER, PR and HER2, as well as other markers of Trop2, PD‐1, EGFR, GRPR and PSMA.
Tan Y, Zeng C, Wang J, Ma F.
europepmc   +2 more sources

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Journal of Clinical Oncology, 2019
PURPOSE The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
S. Tolaney, Hao Guo, S. Pernas, William T. Barry, D. Dillon, Lauren Ritterhouse, Bryan P. Schneider, F. Shen, K. Fuhrman, Michele Baltay, C. Dang, D. Yardley, B. Moy, P. Marcom, K S Albain, H. Rugo, M. Ellis, I. Shapira, A. C. Wolff, L. Carey, B. Overmoyer, A. Partridge, C. Hudis, I. Krop, H. Burstein, E. Winer   +25 more
semanticscholar   +1 more source

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
A phase IV, single‐arm, open‐label, multicenter study assessing the safety and efficacy of trastuzumab emtansine in Indian patients for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive unresectable locally advanced or metastatic breast cancer who received prior treatment with trastuzumab and a taxane.
Sudeep Gupta, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal, Vinod Raina, Vaibhav Watts   +13 more
wiley   +1 more source

Cost-Utility Analysis of Trastuzumab in Treatment Of Metastatic Her2-Positive Breast Cancer in Vietnam [PDF]

, 2014
TT Nguyen, Thuy Thi Nguyen
openalex   +1 more source